2024
-
Article: Certainly Uncertain: An Analysis of the Patent Eligibility Restoration Act of 2023, 13 American University Business Law Review (forthcoming 2024)
- With Joshua D. Sarnoff
-
Book Chapter: If Not Patents, Then Trade Secrets? (forthcoming 2024)
- In Research Handbook on Trade Secrecy in Data and Data Infrastructure
-
Amicus Brief: Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc., No. 23-1169 (Fed. Cir. Aug. 22, 2024)
- For 15 Scholars of Law and Medicine
- Book: The Barons and the Mob: Essays on Centralized Platforms and Decentralized Crowds (Charles Duan & James Grimmelmann, 2024) ssrn
-
Amicus Brief: Carroll Shelby Licensing Inc. v. Halicki, Nos. 23-3731, -4008 (9th Cir. filed Nov. 21, 2023)
- For 20 Professors of Law and Public Knowledge
- Online Article: USPTO Seeks Public Input on Patents and the Right to Research, InfoJustice, July 10, 2024
-
Article: Examining Patent Eligibility, 97 St. John’s Law Review 47 (2023) ssrn
- A little-studied 2011 Federal Circuit decision had major ripple effects on patent eligibility and examination practice, in ways that challenge dominant policy narratives about the doctrine.
- Award: Best Publication of 2023 on Antitrust and Intellectual Property, Jerry S. Cohen Memorial Fund Writing Award, for Mandatory Infringement, 2024.
- Book Chapter: Toward a Legal Framework for Patient Access to At-Home Health Care Device Data (2024) ssrn
- Book Chapter: Patent Title Insurance (2024)
-
Article: Content Moderation on End-to-End Encrypted Systems: A Legal Analysis, 8 Georgetown Law Technology Review 1 (2024) ssrn
- With James Grimmelmann
- Computer scientists have come up with cutting-edge technologies for content moderation on end-to-end encrypted platforms. Are those technologies legal?
- Book: Stephen Clowney et al., Open Source Property: AUWCL Edition (Charles Duan, 2024)
2023
-
Essay: Securing Patent Law, 11 Belmont Law Review 91 (2023) ssrn
- The conversation on intellectual property and national security needs to focus more on technological competitor nations’ potential use of U.S. patents as an offense strategy.
-
Amicus Brief: Green v. United States Department of Justice, No. 23-5159 (D.C. Cir. July 13, 2023)
- For Public Knowledge, the Digital Right to Repair Coalition, Software Freedom Conservancy, iFixit, the Open Source Hardware Association, and Scholars of Property and Technology Law
-
Amicus Brief: Jazz Pharmaceuticals v. Becerra, No. 1:23-cv-1819 (D.D.C. Oct. 24, 2023)
- For 22 Narcolepsy Patients, Public Interest Organizations, Medical Professionals, and Professors of Law
-
Article: On the Appeal of Drug Patent Challenges, 72 American University Law Review 1177 (2023) ssrn
- Empirically, inter partes review patent challenges have been accurate and effective at lowering drug prices. But the Federal Circuit’s publication practices hide those facts.
-
Article: Mandatory Infringement, 75 Florida Law Review 219 (2023) ssrn
- Exploring the unexpected effects of intellectual property/regulation overlaps on market power, innovation incentives, and intellectual property theory.
-
Hearing Testimony: Intellectual Property and Strategic Competition with China: Part I, House of Representatives, 117th Cong. (2023)
- Invited witness before the Subcomm. on Courts, Intellectual Property, and the Internet of the H. Comm. on the Judiciary
2022
-
Book Chapter: A Failure to Interoperate: The Lost Mars Climate Orbiter (2022)
- In “You Are Not Expected to Understand This”: How 26 Lines of Code Changed the World
- A failed NASA mission’s lessons for modern information and Internet technology.
-
Article: Pharmaceutical Patent Two-Step: The Adverse Advent of Amarin v. Hikma Type Litigation, 12 New York University Journal of Intellectual Property and Entertainment Law 1 (2022)
- With S. Sean Tu
- Buried within a tangled web of patents surrounding a widely used cardiovascular drug are the seeds of a legal strategy that could delay generics for years to come.
-
Amicus Brief: American Society for Testing & Materials v. Public.Resource.Org, Inc., 82 F.4th 1262 (D.C. Cir. 2022)
- For Former Government Publishing Officials Raymond A. Mosley and Robert C. Tapella
-
Press Article: Prevent a Legal Catch-22 That Could Push Thousands of Generic Drugs Off the Market, Los Angeles Times, Sept. 21, 2022, at A13
- With Michael A. Carrier & S. Sean Tu
-
Amicus Brief: Teva Pharmaceuticals USA v. GlaxoSmithKline LLC, No. 22-37 (U.S. July 11, 2022)
- For 42 Professors of Law, Economics, Business, and Medicine
Last updated: Tue, 14 Jan 2025 10:20:53 -0500